Icon

Vumerity - (231 mg; Capsule delayed release)

Diroximel fumarate Biogen
231 mg; Capsule delayed release
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
None None
Vumerity is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Yes
**** ** ***. **** ***** * **** ** ** *** ******* *** *** *********. ** ****** **** **** **** ****** ** *** ****. ********* ** ****** *** ******, ******** ****** ** ******** ****** ** *** ****. **, **** ** *** ******** *** ****** *** ******* ****** ****. ***** ***** ***** ** **** (******) *** *** *********.
Vumerity Patent 1 Patent 2 Patent 3
**** ******* ******* *******
***** ****** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* *** **, **** ******* **** ***** *** **** (******** ******)
***** ****** ** \ ** *** **, **** ******* **** ***** *** **** (******** ******)
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** *, **** :
  3. *** *, **** : **** ******** ****** ********* *** **** ** ******.
  4. *** **, **** : ****** ***** * **** ******* **** ** ******* '***, '*** *** '***
  5. *** *, **** : ****** ******* **** **** ** *********** *****.
  6. *** *, **** : ****** *** **** ******* ********** ** ******* *****.
  7. *** **, **** : ***** ******** ****** ** ***** **** ** ******.
  8. *** *, **** : ****** **** ***** **** ************ ** ******* '***, '*** *** '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.